论文部分内容阅读
目的探讨糖皮质激素(GC)对重症肌无力(MG)患者白细胞介素-6(IL-6)和乙酰胆碱受体抗体(AchRab)的影响.方法采用ELISA法检测32例MG患者在用GC治疗前、治疗3个月后和20例正常对照者的血清IL-6和AchRab水平.结果MG患者血清IL-6和AchRab水平均显著高于对照组(P＜0.01)GC治疗能明显降低其水平(P＜0.05或P＜0.01),且对不同性别、年龄、病程、临床类型和不同预后的MG患者均有作用(P＜0.05或P＜0.01),但在GC治疗前后,预后差的MG患者血清IL-6和AchRab水平始终高于预后好者(P＜0.05).血清IL-6水平在AchRab阳性MG患者高于AchRab阴性患者(P＜0.05),且与AchRab滴度呈正相关(f=0.710,P＜0.01).结论GC可通过抑制MG患者体内IL-6和AchRab的产生,有效调节机体细胞免疫和体液免疫功能.“,”Objective:To investigate the effect of glucocorticosteroid (GC) on interleukin-6 (IL-6) and acetyl choline receptor antibody (AchRab) of myasthenia gravis (MG) patients. Methods: The serum IL-6 and AchRab levels were measured in 32 MG patients before and after treated with GC and in 20 controls with ELISA. Results: The serum IL-6 and AchRab levels of MG patients were both significantly higher than those of controls (P ＜0.01), but dramatically decreased after 3 months treatment with GC (P ＜0.05 or P ＜0.01). GC could dramatically decrease both the IL-6 and the AchRab levels in different sex, age, course, clinical type and prognosis MG patients (P ＜0.05 or P ＜0.01). The serum IL-6 and AchRab levels of MG patients whose prognosis was bad were higher than those in patients with better prognosis both before and after treatment with GC (P ＜0.05). The serum IL-6 levels of MG patients whose serum AchRab was positive were higher than those in patients whose serum AchRab was negative (P ＜ 0.05). The serum IL-6 and AchRab levels of MG patients were positively correlated (r =0.710, P ＜0.01). Conclusions: GC can effectively regulate the function of both cellular immunity and humoral immunity by decreasing the production of IL-6 and AchRab.